Infliximab population pharmacokinetic modelling in patients with Inflammatory Bowel Disease (IBD): Patient factors influencing infliximab pharmacokinetics

被引：0
|
作者：
Guardiola, J. [1 ]
Rodriguez-Alonso, L. [1 ]
Santacana, E. [2 ]
Padulles, N. [2 ]
Colom, H. [3 ]
Padulles, A. [2 ]
Arajol, C. [1 ]
Ruiz-Cerulla, A. [1 ]
Cobo, S. [2 ]
Bas, J. [4 ]
Climent, J. [4 ]
Morandeira, F. [4 ]
Rodriguez-Moranta, F. [1 ]
机构：
[1] Hosp Univ Bellvitge, Gastroenterol, Lhospitalet De Llobregat, Spain
[2] Hosp Univ Bellvitge, Pharm, Lhospitalet De Llobregat, Spain
[3] Univ Barcelona, Sch Pharm, Pharmacokinet, Barcelona, Spain
[4] Hosp Univ Bellvitge, Immunol, Lhospitalet De Llobregat, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2015年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P453
引用
收藏
页码：S306 / S307
页数：2
相关论文
共 50 条
  • [31] Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
    Bevers, Nanja C.
    Keizer, Ron J.
    Wong, Dennis R.
    Aliu, Arta
    Pierik, Marieke J.
    Derijks, Luc J. J.
    van Rheenen, Patrick F.
    CLINICAL PHARMACOKINETICS, 2024, 63 (04) : 529 - 538
  • [32] Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease
    Bauman, Laura E.
    Xiong, Ye
    Mizuno, Tomoyuki
    Minar, Philip
    Fukuda, Tsuyoshi
    Dong, Min
    Rosen, Michael J.
    Vinks, Alexander A.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (03) : 429 - 439
  • [33] Trough serum infliximab level, anti-infliximab antibody status and response to infliximab maintenance treatment in inflammatory bowel disease (IBD)
    Kong, J. Y.
    Bundell, C. S.
    Pawlik, J.
    Hollingsworth, P. N.
    Forbes, G. M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 59 - 60
  • [34] A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease
    Brandse, Johannan F.
    Mould, Diane
    Smeekes, Oscar
    Ashruf, YaeL
    Kuin, Sabine
    Strik, Anne
    van den Brink, Gijs R.
    D'Haens, Geert R.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (04) : 650 - 660
  • [35] The Effect of Infliximab and Adalimumab Treatment on Angiogenic Factor Levels in Patients With Inflammatory Bowel Disease (IBD)
    Algaba, Alicia
    Linares, Pablo M.
    Contreras, Maria Encarnacion Fernandez
    Figuerola, Ariadna
    Calvet, Xavier
    Guerra, Ivan
    Villa, Jose Carlos
    Chaparro, Maria
    Agullo, Jose Luis Rodriguez
    Gisbert, Javier P.
    Bermejo, Fernando
    GASTROENTEROLOGY, 2012, 142 (05) : S869 - S870
  • [36] The Risk of Developing Cancer in Patients With Inflammatory Bowel Disease (IBD): Does Infliximab Contribute to Risk?
    Askari, Alan
    Currie, Andrew
    Nachiappan, Subramanian
    Akbar, Ayesha
    Bottle, Alex
    Athanasiou, Thanos
    Faiz, Omar
    GASTROENTEROLOGY, 2016, 150 (04) : S574 - S575
  • [37] Use of infliximab in pediatric patients with inflammatory bowel disease
    Serrano, MS
    Schmidt-Sommerfeld, E
    Kilbaugh, TJ
    Brown, RF
    Udall, JN
    Mannick, EE
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (7-8) : 823 - 828
  • [38] The use of Infliximab in Older Inflammatory Bowel Disease Patients
    Moleski, Stephanie M.
    Lindenmeyer, Christina C.
    Kozuch, Patricia L.
    GASTROENTEROLOGY, 2012, 142 (05) : S361 - S361
  • [39] IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab
    Urcelay, Elena
    Luis Mendoza, Juan
    Martinez, Alfonso
    Fernandez, Laura
    Taxonera, Carlos
    Diaz-Rubio, Manuel
    de la Concha, Emilio G.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (08) : 1187 - 1192
  • [40] The effect of infliximab infusion on semen quality in men with inflammatory bowel disease (IBD)
    Mahadevan, U
    Turek, PJ
    GASTROENTEROLOGY, 2004, 126 (04) : A467 - A467
12345